Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Wegovy pen is a pre-filled, disposable injection device made by Novo Nordisk. Each colour-coded pen delivers a fixed dose of semaglutide and is designed to be used once weekly. Knowing what your pen looks like before you open the box matters — it helps you confirm the right dose, spot a damaged device, and inject with confidence. These are prescription-only medicines, so the pen you receive will be whichever dose your prescriber has assessed as right for you. This page walks through what each pen looks like, how to read the label, and what to check before every injection.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Every Wegovy pen shares the same basic anatomy. A clear viewing window sits near the base of the pen so you can see the liquid inside; the solution should look clear and colourless, without particles or cloudiness. At the top is a green start button, and a yellow injection indicator moves into view once the dose has been delivered. The needle is hidden inside a grey needle cap and covered by a needle shield that retracts automatically on contact with skin, you press, you hold for ten seconds, and the mechanism does the rest. Many people who are nervous about self-injecting find this reassuring. If you'd like a fuller explanation of how the device works in practice, the Wegovy pen guide covers each physical step in detail.
The pen is designed for single use only. Once you have injected your weekly dose, the device locks and the viewing window turns red. At that point it should go straight into a sharps container rather than a household bin. Never try to reuse a pen or remove the needle yourself.
This is the decision most people are trying to make when they search for pen pictures. Novo Nordisk uses a distinct colour band on each Wegovy pen's label, and the colour changes as the dose escalates. The titration pathway runs from 0.25 mg through 0.5 mg, 1.0 mg, 1.7 mg, to the 2.4 mg maintenance dose. The 0.25 mg starter pen and the higher-dose pens look almost identical in shape and size, colour coding is the fastest visual check that you have the right pen in hand. Before every injection, read the label: confirm the strength printed on it matches what your prescriber has prescribed, and check the expiry date.
The solution volume also changes slightly between doses. If you want to understand how the fill volume relates to the dose markings on the barrel, the Wegovy pen volume guide sets that out clearly. As a rule of thumb, if anything on the label looks unusual, the liquid appears discoloured, or the pen looks physically damaged, do not inject, contact your prescriber or pharmacist.
The MHRA's patient-level NHS information on semaglutide (Wegovy) includes a full list of what to check before injecting and when to seek urgent help; it's worth keeping that page bookmarked alongside your Patient Information Leaflet.
Many patients encounter the phrase Wegovy pink pen and wonder whether it refers to a specific dose. The pink branding is associated with the 1.7 mg device in the standard titration sequence, though device colours are subject to Novo Nordisk's packaging decisions and may vary by batch or market. Always treat the printed dose on the label as the definitive guide, colour is a useful secondary check, not the primary one.
In January 2026 a 7.2 mg maintenance dose received MHRA approval; in April 2026 a dedicated single-dose 7.2 mg pen followed, designed with an auto-dosing mechanism, built-in covered needle and a lock-after-use feature. The titration pathway to 7.2 mg still begins at 0.25 mg and steps up under prescriber guidance. Whether a specific pen format is available to you is something confirmed at clinical assessment, a prescriber considers your full health picture before any dose or format is confirmed. You can read more about the full Wegovy treatment overview if you're still weighing up whether it's right for you.
A question our prescribers hear regularly: does the pen need to come out of the fridge before injecting? The answer is in the Patient Information Leaflet (the authoritative source for your specific pen), but many patients find it most practical to keep pens on the fridge door shelf rather than at the back where temperatures can dip lower. The pen should not be frozen; if it has been, discard it.
Before injecting, most people build a brief routine: take the pen from the fridge, check the label and expiry, look through the viewing window, clean the injection site with an alcohol swab and let it dry, then attach to the skin and press the green button. The sites licensed for injection are the abdomen, the front of the thigh, or the upper arm, rotate each week to avoid tissue irritation. Inject a different spot within the same area, not the exact same point.
For context on how Wegovy compares with other semaglutide-based injections, it helps to understand that Ozempic contains the same active ingredient but carries a different licence, it is authorised for type 2 diabetes, not weight management. Wegovy is the weight-management licence. The weight-loss treatments overview explains the difference plainly if you're earlier in the decision process.
If you've worked through the pictures and instructions and feel ready to explore whether Wegovy is clinically suitable for you, start your free consultation with our prescribers, a real clinician reviews every submission the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.